Tocilizumab for giant cell arteritis

Antonio, Aileen; Santos, Ronel N; Abariga, Samuel A

doi:10.1002/14651858.cd013484.pub3

Cited by 12 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Targeted treatment with subcutaneous Tocilizumab (TCZ) has shown significant glucocorticoid-sparing effects in new-onset and relapsing patients with GCA [132][133][134]. TCZ is a monoclonal antibody directed against the IL-6 receptor that inhibits signalling by the pro-inflammatory cytokine IL-6 [135].…”

Section: Management Of Gcamentioning

confidence: 99%

Giant cell arteritis: reviewing the advancing diagnostics and management

Bilton

Mollan

2023

Eye

View full text Add to dashboard Cite

Giant Cell Arteritis (GCA) is well known to be a critical ischaemic disease that requires immediate medical recognition to initiate treatment and where one in five people still suffer visual loss. The immunopathophysiology has continued to be characterised, and the influencing of ageing in the development of GCA is beginning to be understood. Recent national and international guidelines have supported the directed use of cranial ultrasound to reduce diagnostic delay and improve clinical outcomes. Immediate high dose glucocorticoids remain the standard emergency treatment for GCA, with a number of targeted agents that have been shown in clinical trials to have superior clinical efficacy and steroid sparing effects. The aim of this review was to present the latest advances in GCA that have the potential to influence routine clinical practice.

show abstract

Section: Management Of Gcamentioning

confidence: 99%

Giant cell arteritis: reviewing the advancing diagnostics and management

Bilton

Mollan

2023

Eye

View full text Add to dashboard Cite

show abstract

“…46,49,50 IL-6 blockade, however, lacks sufficient evidence to be an isolated treatment strategy in GCA and TKA; therefore, more research is necessary to ascertain the efficacy of IL-6 blockade. 51 Another steroid-sparing option in LVV is mycophenolate mofetil (MMF). MMF is a purine synthesis inhibitor.…”

Section: Treatmentmentioning

confidence: 99%

Large-Vessel Vasculitis in Ophthalmology: Giant Cell Arteritis and Takayasu Arteritis

Dhanani

Zhao

Charoenkijkajorn

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Giant cell arteritis and Takayasu arteritis are large-vessel vasculitides that share multiple common features but also have significant differences in epidemiology, demographics, clinical presentation, evaluation, and treatment. Giant cell arteritis is more common in elderly patients of Caucasian descent versus Takayasu arteritis, which is more prevalent in younger patients of Asian descent. Although traditionally age has been the main criterion for differentiating the 2 etiologies, modifications in the diagnostic criteria have recognized the overlap between the 2 conditions. In this monograph, we review the diagnostic criteria for both conditions and describe the epidemiology, pathogenesis, histology, evaluation, and management for large-vessel vasculitis in ophthalmology. Additionally, we describe ocular imaging techniques that may be utilized by ophthalmologists to identify manifestations of large-vessel vasculiti- des in patients. Lastly, we compare and contrast the key clinical, laboratory, and pathologic features that might help ophthalmologists to differentiate the 2 entities.

show abstract

“…Tocilizumab, which is a recombinant humanized anti-human monoclonal antibody against soluble and membrane-bound interleukin-6 receptors (IL-6R) of the immunoglobulin G1 (IgG1) subclass, was approved in Europe in September 2017 and by the US Food and Drug Administration in May 2017 for the treatment of patients with GCA. 1,3 Adjunctive treatment using tocilizumab is recommended in refractory/relapsing GCA, in patients who already developed/have increased risk of glucocorticoid-related adverse effects/complications. 4 A Cochrane Review by Antonio et al 1 evaluated the effectiveness and safety of tocilizumab in patients with GCA.…”

Section: Backg Rou N Dmentioning

confidence: 99%

“…Moderate-certainty evidence showed that the time to first relapse following remission is longer at 12 months or more in patients who received tocilizumab, while all-cause mortality is similar between groups. 1 Patients with GCA may experience comorbidities associated with the disease itself and/or due to the medications used during the disease course. 2 Increasing remission rate and relapse-free survival rate, tocilizumab might be beneficial in lowering the risk of GCA-related morbidities.…”

Section: What Are the Implic Ati On S Of The Co Chr Ane E Viden Ce Fo...mentioning

confidence: 99%

How beneficial and safe is tocilizumab for patients with giant cell arteritis? A Cochrane Review summary with commentary

Benlidayı

2022

Int J of Rheum Dis

View full text Add to dashboard Cite

Tocilizumab for giant cell arteritis

Cited by 12 publications

References 42 publications

Giant cell arteritis: reviewing the advancing diagnostics and management

Giant cell arteritis: reviewing the advancing diagnostics and management

Large-Vessel Vasculitis in Ophthalmology: Giant Cell Arteritis and Takayasu Arteritis

How beneficial and safe is tocilizumab for patients with giant cell arteritis? A Cochrane Review summary with commentary

Contact Info

Product

Resources

About